India sees early competition in semaglutide as drugmakers prepare lower-cost versions

Summary

Indian drugmakers are preparing to launch lower-cost versions of semaglutide, the key ingredient in Ozempic and Wegovy, subject to patent and regulatory pathways.

Companies including Natco Pharma, Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories are among those exploring market entry.

Increased competition is expected to improve affordability of diabetes and obesity treatments in India over time.

NEW DELHI, March 20, 2026 — Indian pharmaceutical companies are stepping up efforts to introduce more affordable versions of semaglutide, a widely used treatment for type 2 diabetes and obesity, as interest in the therapy grows globally.

Semaglutide, sold by Novo Nordisk under the brand names Ozempic and Wegovy, has seen strong demand worldwide, prompting Indian drugmakers to explore opportunities to manufacture similar products where legally permissible.

Several companies, including Natco Pharma, Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories, have indicated plans to develop or launch semaglutide-based treatments in India, although timelines and pricing details remain subject to regulatory approvals and patent considerations.

Pricing and access in focus

Industry executives say competition from multiple manufacturers could gradually bring down treatment costs in India, where access to advanced therapies remains limited for many patients.

While some companies are evaluating different delivery formats such as vials and pre-filled pens, there is no confirmed industry-wide pricing benchmark yet. Market analysts expect that locally produced versions could be priced lower than imported branded products over time.

Regulatory and patent landscape

The availability of generic or alternative versions of semaglutide depends on India’s patent framework and regulatory clearances. Analysts note that any large-scale rollout will hinge on compliance with intellectual property rules and approvals from the country’s drug regulator.

India has previously seen similar trends in other therapeutic areas, where domestic competition helped expand access after patent barriers eased or licensing arrangements were established.

Growing demand for metabolic therapies

Demand for GLP-1 receptor agonists such as semaglutide is rising globally, driven by increasing cases of diabetes and obesity. India, which has one of the largest populations of diabetes patients, is seen as a key growth market for such treatments.

Why this matters

• Healthcare access: Lower-cost alternatives could expand access to advanced diabetes and weight-management therapies.
• Market competition: Entry of multiple Indian drugmakers may increase competition and gradually reduce prices.
• Regulatory clarity: The pace of adoption will depend on patent status and approvals, making policy developments critical.

FAQs

Q1. Is semaglutide available as a generic drug in India?

Availability depends on patent status and regulatory approvals. Multiple companies are working toward launching versions where permitted.

Q2. Will prices fall significantly?

Prices may decline over time as competition increases, but no confirmed pricing has been officially announced across the industry.

Q3. Which companies are entering this segment?

Indian firms such as Natco Pharma, Sun Pharmaceutical Industries and Dr. Reddy’s Laboratories have expressed interest in semaglutide-based products.